Nobody was proven wrong about Elto just because of
Post# of 30027
(Total Views: 404)
Posted On: 01/04/2018 11:59:04 PM
Nobody was proven wrong about Elto just because of patent issuances.
I’ve been in the pharma industry for almost 25 years, with colleagues across several companies in this CNS/Parkinson’s space including my own extensive experience. Adamas took an old drug, Amantidine, actually got trials done and got approval for PLID last August. I asked about the potential of eltoprazine as a competitor. The response was “no studies for almost 10years, no other companies interested, why would another company even pick it up at this point.” Nobody is buying the Nov 2015 announcement of phase 2 data in 20 Alzheimer’s aggression patients. Alzheimer’s aggression and Agitation are two of the hottest areas in CNS and NOBODY is interested in Elto.
Maybe our leadership’s track record changes in the future and I hope it does, but I’ve been fooled multiple times here before and I’m not buying it 7ntil we see something concrete that actually creates a real value proposition.
Remember how we were told convincingly that Lympro was moving into its commercialization cycle and that it would “change the math” by GC? That was years ago. He has to accomplish something legit to convince me it’s time to get in any further. With that said, I look forward to being proven wrong very soon. I will gladly take the “I told you so” from everyone here. But Elto isn’t the answer.
I’ve been in the pharma industry for almost 25 years, with colleagues across several companies in this CNS/Parkinson’s space including my own extensive experience. Adamas took an old drug, Amantidine, actually got trials done and got approval for PLID last August. I asked about the potential of eltoprazine as a competitor. The response was “no studies for almost 10years, no other companies interested, why would another company even pick it up at this point.” Nobody is buying the Nov 2015 announcement of phase 2 data in 20 Alzheimer’s aggression patients. Alzheimer’s aggression and Agitation are two of the hottest areas in CNS and NOBODY is interested in Elto.
Maybe our leadership’s track record changes in the future and I hope it does, but I’ve been fooled multiple times here before and I’m not buying it 7ntil we see something concrete that actually creates a real value proposition.
Remember how we were told convincingly that Lympro was moving into its commercialization cycle and that it would “change the math” by GC? That was years ago. He has to accomplish something legit to convince me it’s time to get in any further. With that said, I look forward to being proven wrong very soon. I will gladly take the “I told you so” from everyone here. But Elto isn’t the answer.
(3)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼